Michael Shultz

Company: ViewPoint Therapeutics

Job title: Co-founder & Chief Scientific Officer,

Seminars:

Pb-203 Image-Guided Pb-212 Alpha Particle Therapy for Cancer – Preclinical Evidence of a Potent Paradigm 11:30 am

Exploring the rationale behind exploring behind selecting newer isotopes Considering side effects and efficacy: which combinations can complement these novel isotopes to address these challengesRead more

day: Day One Track A AM